Clinical trial NCT00957086: Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer
Official title: Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Carcinoma, Squamous Cell of Head and Neck
Keywords: Phase III Adjuvant Concurrent Chemo-RT +/- nimotuzumab
Lead sponsor: National Cancer Centre, Singapore
Sponsor class: OTHER
Collaborators: name: National Medical Research Council (NMRC), Singapore
name: Innogene Kalbiotech Pte. Ltd
First posted: 2009-08-12
Enrollment: 710
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to improve the loco-regional control rate and overall survival of locally advanced head and neck squamous carcinoma (HNSCC). The investigators hypothesize that the addition of nimotuzumab (a recombinant humanized murine immune antibody that blocks both epidermal growth factor (EGF) and transforming growth factor (TGF)) to the current gold standard of concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after resection of their locally advanced HNSCC will confer therapeutic advantage.

Detailed description: The aim of the study is to improve the loco-regional control rate and overall survival of locally advanced head and neck squamous carcinoma (HNSCC). We hypothesize that the addition of nimotuzumab (a recombinant humanized murine immune antibody that blocks both epidermal growth factor (EGF) and transforming growth factor (TGF)) to the current gold standard of concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after resection of their locally advanced HNSCC will confer therapeutic advantage. We have designed a phase III randomized study that includes a placebo arm. We assume a 10% increase in 2 year disease free survival (from 60% to 70%). To achieve statistical significance at 90% power, we calculate the need for 355 patients per arm, assuming also a 10% dropout rate. We aim to accomplish this study with the involvement of a multidisciplinary team of surgical, radiation and medical oncologists actively involved in the management of HNSCC coming from multiple institutions and spanning at least 12 different countries. For quality assurance we will have the involvement of Singapore Clinical Research Institute who will lead the data coordination and ensure fidelity of data collected and statistical analysis; the European Society of Therapeutic Radiation Oncology (EQUAL-ESTRO) for radiation dose and fields and an international independent panel of medical oncologist, radiation oncologist and biostatistician for the Data Monitoring Committee (DMC). This committee will monitor significant events and advise on continuation or termination of trial. Concurrent with the randomized trial, we will be collecting bio specimens including blood, tumour and saliva, pre-treatment and on completion of surgical resections. We hypothesize that there are important biomarkers including clusters of genes, cancer stem cells that will predict prognosis and treatment response. The analyses performed will be very powerful because of the large sample size, the specimens are collected prospectively and because the statistical analyses will be multivariate, incorporating not only treatment but biological and staging data.

Eligibility criteria: Inclusion Criteria:

* Age should be greater than or equal to the minimum age of consent in the applicable country
* Histologically proven head and neck squamous cell cancer (excluding nasopharynx, salivary glands, paranasal sinuses and unknown primaries) on biopsy of the primary lesion or the neck mass.
* Resectable stage III/IV according to the AJCC/UICC staging system with no evidence of distant metastasis.
* Complete macroscopic resection.
* Patients should have at least one of the following pathological features for inclusion: pT3 or pT4 and any nodal stage (N), except T3N0 of the larynx, with negative resection margins, or a tumor stage of 1 or 2 with a nodal stage of 2 or 3 and no distant metastasis (M0); patients with stage T1 or T2 and N0 or N1 who had unfavorable pathological findings (extranodal spread, positive resection margins, perineural involvement, or vascular tumor embolism) are also eligible, as are those with oral-cavity or oropharyngeal tumors with involved lymph nodes at level IV or V.
* Performance status must be ECOG 0 or 1. Patients should be able to tolerate chemotherapy and radiotherapy.
* Adequate bone marrow, renal and hepatic function:

  1. WBC\>3000/mm3, platelets\>100000/mm3
  2. Serum creatinine\<upper limit of normal range as per institution and calculated creatinine clearance (according to the Cockcroft and Gault method) \>50 ml/min.
  3. SAP, SGOT\<2 x upper limit of normal range, bilirubin \<1.5 x upper limit of normal range.
* Written informed consent.

Exclusion Criteria:

* Histology other than SCC or its subtype.
* Patients with disease subsite deemed suitable for organ preservation approach, namely stage III/IV laryngeal or hypopharyngeal carcinoma with not more than low-volume T4 disease; low-volume T4 disease is defined as disease not eroding into cartilage or extending not more than 1 cm into the base of tongue.
* Clinical or radiological evidence of distant metastasis.
* Uncontrolled comorbidities such as diabetes mellitis, hypertension, cardiac disease.
* Uncontrolled infection.
* Uncontrolled hypercalcemia.
* Prior history of cancer less than 5 years ago or a synchronous primary outside the head and neck area.
* Prior treatment, head and neck radiotherapy, chemotherapy or surgery (excluding biopsy) or anti-EGFR therapy such as cetuximab/EGFR oral tyrosine kinase inhibitor.
* Patients for whom compliance with follow-up is unlikely.

Primary outcomes:
measure: To compare the disease-free survival between patients randomized to adjuvant nimotuzumab/cisplatin/RT with the control arm
timeFrame: 5 years
Secondary outcomes:
measure: To compare the overall survival between the two arms
timeFrame: 5 years
measure: To assess the Toxicity Profile between the 2 arms
timeFrame: 5 years
Other outcomes:
Locations:
city: Bedford Park
country: Australia
facility: Flinders Medical Centre
city: Melbourne
country: Australia
facility: Peter MacCallum Cancer Centre
city: Vedado
country: Cuba
facility: National Institute of Oncology and Radiobiology
city: Alexandria
country: Egypt
facility: Alexandria University School of Medicine
city: Cairo
country: Egypt
facility: National Cancer Institute, Cairo University
city: Bangalore
country: India
facility: Apollo Hospital Bangalore
city: Bangalore
country: India
facility: Narayana Hrudayalaya Hospital (Mazumdar Shaw Cancer Institute)
city: Kerala
country: India
facility: Amrita Institute of Medical Sciences
city: Mumbai
country: India
facility: Tata Memorial Centre
city: Tamil Nadu
country: India
facility: Christian Medical College
city: Trivandrum
country: India
facility: Regional Cancer Center Trivandrum, India
city: Jakarta
country: Indonesia
facility: Cipto Mangunkusumo General Hospital Indonesia
city: Gyeonggi-do
country: Korea, Republic of
facility: National Cancer Center Korea
city: Incheon
country: Korea, Republic of
facility: INHA University Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
city: Kuala Lumpur
country: Malaysia
facility: Pantai Medical Centre, Kuala Lumpur
city: Melaka
country: Malaysia
facility: Mahkota Medical Center
city: Manila
country: Philippines
facility: University of Santo Tomas Hospital
city: Quezon City
country: Philippines
facility: St. Luke's Medical Center
city: Riyadh
country: Saudi Arabia
facility: King Fahad Medical City
city: Singapore
country: Singapore
facility: National Cancer Centre
city: Durban
country: South Africa
facility: The Oncology Centre
city: Panorama
country: South Africa
facility: GVI Oncology
city: Taichung
country: Taiwan
facility: China Medical University Hospital
city: Taipei
country: Taiwan
facility: Taipei Med Univ Hosp [TMUH]
city: Taipei
country: Taiwan
facility: Taipei Veteran General Hospital
city: Bangkok
country: Thailand
facility: National Cancer Institute Bangkok (+Chulabhorn for RT)
city: Bangkok
country: Thailand
facility: Siriraj Hospital
city: Chiang Mai
country: Thailand
facility: Chiang Mai Hospital
Study officials:
affiliation: National Cancer Centre
name: K C Soo, Prof
role: STUDY_CHAIR
References: